Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785213 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone
A Phase 1 study, sponsored by Mutual Pharmaceutical Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00785213 is a Phase 1 study that has completed, run by Mutual Pharmaceutical Company. The registered enrollment target is 23 participants.
The verdict
NCT00785213, a Phase 1 study, has completed, sponsored by Mutual Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Rosiglitazone is predominantly metabolized by cytochrome P450 (CYP) 2C8. Quinine sulfate is an inhibitor of CYP 2C8. This study will evaluate the effect of multiple doses of quinine sulfate at steady-state on the pharmacokinetics of single-dose rosiglitazone in healthy adult subjects.
Interventions
- DRUG Rosiglitazone 4 mg Tablets
- DRUG Quinine Sulfate 324 mg Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785213
The ClinicalTrials.gov registry entry for NCT00785213 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mutual Pharmaceutical Company, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosiglitazone 4 mg Tablets is the first listed.
NCT00785213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00785213 about?
NCT00785213 is a clinical study titled "Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone". Rosiglitazone is predominantly metabolized by cytochrome P450 (CYP) 2C8. Quinine sulfate is an inhibitor of CYP 2C8. This study will evaluate the effect of multiple doses of quinine sulfate at steady-state on the pharmacokinetics of single-dose rosiglitazone in healthy adult subjects.
What is the current status of trial NCT00785213?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2008-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00785213?
The interventions under investigation include: Rosiglitazone 4 mg Tablets (DRUG), Quinine Sulfate 324 mg Capsules (DRUG).
Who is sponsoring clinical trial NCT00785213?
This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.